MVP Chemotherapy in Small-Cell Lung Cancer
Author Information
Author(s): TF Hickish, IE Smith, MC Nicolson, S Ashley, K Priest, L Spencer, A Norman, G Middleton, MER O'Brien
Primary Institution: Royal Marsden Hospital
Hypothesis
Is MVP chemotherapy effective in treating small-cell lung cancer?
Conclusion
MVP chemotherapy is effective in treating small-cell lung cancer with low toxicity.
Supporting Evidence
- 79% overall response rate with 17% complete response and 62% partial response.
- Median survival was 10 months for limited disease patients and 6 months for extensive disease patients.
- Quality of life improved significantly in emotional and cognitive functioning.
Takeaway
Doctors tested a new medicine called MVP on patients with lung cancer, and it helped many of them feel better without making them very sick.
Methodology
Fifty previously untreated patients with small-cell lung cancer received MVP chemotherapy and were monitored for response and toxicity.
Limitations
The study had a small sample size and was a pilot trial.
Participant Demographics
33 men and 17 women, median age 66 years (range 46-83 years).
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 78-96%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website